Emalex Biosciences Funding: $285M Raised, Series D (2022)
Emalex Biosciences is based in Northbrook. It has raised $285M in total funding. Latest round: Series D.
Emalex Biosciences funding overview
Emalex Biosciences is based in Northbrook. Emalex Biosciences has raised $285M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series D announced in November 2022. The round record for Emalex Biosciences runs through 2022; nothing later has been disclosed. Investors on record include Fidelity Investments, Paragon Biosciences, Horizon Tech Finance, Valor Equity Partners. 4 distinct backers are named across the disclosed rounds.
Emalex Biosciences at a glance
Total raised
$285M
Latest round
Series D
Latest round date
November 2022
Headquarters
Northbrook
Notable investors
Fidelity Investments, Paragon Biosciences, Horizon Tech Finance, Valor Equity Partners
Frequently asked about Emalex Biosciences funding
How much has Emalex Biosciences raised?
Emalex Biosciences has raised $285M in total disclosed funding across the rounds on record.
Who has invested in Emalex Biosciences?
Fidelity Investments, Paragon Biosciences, Horizon Tech Finance, Valor Equity Partners are named among the investors backing Emalex Biosciences.
What was the latest Emalex Biosciences funding round?
The most recent disclosed round is a Series D, announced in November 2022.
Where is Emalex Biosciences based?
Emalex Biosciences is based in Northbrook.
When did Emalex Biosciences last raise?
The last disclosed Emalex Biosciences round closed in November 2022 at Series D.
Every Emalex Biosciences figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Northbrook at a similar stage.
